Mechanisms for Activation of Beige Adipose Tissue in Humans
Philip Kern
Summary
Mirabegron (Myrbetriq®, Astellas) is a highly specific and well-tolerated ß3 agonist marketed for overactive bladder. This trial will assess the effects of mirabegron on glucose tolerance and adipose tissue in prediabetic patients
Description
Among the many survival adaptations developed by mammals is a defense against the cold and hypothermia; one of these adaptations is the ability to uncouple oxidative phosphorylation and generate heat, rather than adenosine triphosphate (ATP), from lipid substrate in specialized tissues, and there has been much interest in exploiting this inefficient metabolism for the treatment of obesity and insulin resistance. Brown adipose tissue (BAT) protects against obesity in mice, and studies have documented cold-induced BAT in humans using positron emission tomography (PET-CT) scanning. Additional stu…
Eligibility
- Age range
- 35–65 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * BMI 27-45 * prediabetes (A1c 5.7-6.4) * impaired fasting glucose or impaired glucose tolerance Exclusion Criteria: * diabetes * chronic use of anti-diabetic medication * acute or chronic inflammatory condition * unstable medical condition * cancer * renal insufficiency * any contraindication for Mirabegron * BMI \>45
Interventions
- DrugPlacebo
Participants will take one pill (placebo) daily for the first week and two pills daily for the remaining 15 weeks.
- DrugMirabegron
Participants will take one pill (50mg Mirabegron) daily for the first week. For week two, participants will take two pills (50mg and 25mg Mirabegron). Unless there are side effects, for the remaining 14 weeks participants will take two pills (50mg each) daily.
- DrugMirabegron 50 MG
Participants will take one pill (50mg Mirabegron) daily between visit 2 and visit 3
- DrugMirabegron 100 mg
participants will be given 6 weeks of mirabegron (25 mg) and will take 1 pill once per day for 4-6 weeks. Next participants will be given 6 weeks of mirabegron (50 mg) and take 1 pill once per day for 4-6 weeks. Last participants will be given 6 weeks of mirabegron (100 mg) and take 1 pill once per day for 4-6 weeks.
Location
- University of KentuckyLexington, Kentucky